A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Stadtmauer
Edward A
EA
Hematology/Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA, edward.stadtmauer@uphs.upenn.edu.
Lonial
Sagar
S
Vesole
David H
DH
Abonour
Rafat
R
Alsina
Melissa
M
Badros
Ashraf
A
Comenzo
Raymond
R
Durie
Brian
B
Giralt
Sergio
S
Hussein
Mohamad
M
Jakubowiak
Andrzej
A
Mehta
Jayesh
J
Niesvizky
Ruben
R
Orlowski
Robert
R
Siegel
David
D
Singhal
Seema
S
Vescio
Robert
R
Wang
Michael
M
Zangari
Maurizio
M
Munshi
Nikhil C
NC
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide